CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/17/2023
Back to search
Official data from USPTO
BIOHAVEN PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
04/03/2025
Trademark type
Combined
Nice classes
5, 42
Filing date
06/22/2021
Registration date
01/25/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/25/2022
Last transaction
04/03/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
2020-03-00
First use in commerce
2020-03-00
Drawing code
3
Owner type
99
Owner location
Road Town, Tortola, VG
Examiner
CLIFFORD, MEGAN
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "BIOHAVEN PHARMACEUTICALS", with two outlined hexagon shapes positioned above the letter "I" and one outlined hexagon shape positioned below the letter "I", and the wording "PHARMACEUTICALS" appearing in smaller print below the wording "BIOHAVEN".
Holders and representatives
Holders
Biohaven Therapeutics Ltd.
Biohaven Therapeutics Ltd.
Representatives
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicated and pharmaceutical preparationsboth prescription and over-the-counterfor use in connection with humans and animalsfor the treatment of central nervous system disordersneurologic illnessespsychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemiapost-stroke recoverysevere intracranial atherosclerosiscarotid endarterectomycardiac bypasscerebral vasculitisreversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuriespost- intracranial hemorrhage recoverytraumatic brain injuryspinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseasesAlzheimer's disease (AD)Amyotrophic Lateral Sclerosis (ALS)Huntington's diseaseLewy body dementiafrontotemporal dementiavascular dementiaParkinson's diseasecognitive impairment of agingprogressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathiesglaucomadiabetic retinopathyischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of painopioid sparing analgesiacancer painchronic neuropathic painperipheral neuropathylow back pain in the nature of failed back surgery syndromeradiculopathy in the nature of sciaticadiabetic peripheral neuropathypost-herpetic neuralgiachemotherapy induced neuropathy and other medication induced neuropathiescomplex regional pain syndromefibromyalgiachronic post-operative paincluster thoracotomyphantom limbstump neuroma; pharmaceutical preparations for the treatment of headache and facial painheadachemigrainechronic daily headachecluster headachetrigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseasesbreath holding in Rett syndromedystoniasdysphagiagait abnormalitiesbulbar function in Amyotrophic Lateral Sclerosis (ALS)pseudobulbar affectlevodopa-induced dyskinesias in Parkinson's diseaseagitation in Alzheimer's disease (AD)disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsyprecision medicine for the adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorderstreatment resistant depressionPost Traumatic Stress Disorder (PTSD) in the nature of hyperarousalsubstance abuse disordersaddiction disordersObsessive Compulsive Disorder (OCD)hoardingtrichotillomaniaeating disordersGeneralized Anxiety Disorder (GAD)adjustment disorderspanic disordermajor depressive episodebipolar disorder in the nature of manic and depressive episodesdysthymiacyclothymiapsychotic disordersschizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disordersspinocerebellar ataxiaFriedriech's ataxiamultisystem atrophyessential tremor; pharmaceutical preparations for the treatment of hearing disorderstinnitusdeliriumsleep disordersparasomniaslearning disordersAttention Deficit Disorder (ADD)Pervasive Developmental Disorders (PDD)Asperger's syndromeautismmenopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancermonotherapy and adjunctive use
Class 42
Pharmaceutical research and development in the fields of headachefacial painimpulse control disordersneurological disordersneurodegenerative disordersconsultation provided in conjunction therewith
Publications
History of USPTO decisions and trademark events.
22 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/17/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/17/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/17/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/17/2023
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
06/23/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
01/25/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
01/12/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/09/2021
PUBO
PUBLISHED FOR OPPOSITION
11/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/20/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/06/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/21/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/21/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/21/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/10/2021
GNRT
NON-FINAL ACTION E-MAILED
09/10/2021
CNRT
NON-FINAL ACTION WRITTEN
09/10/2021
DOCK
ASSIGNED TO EXAMINER
09/08/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/08/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/07/2021
NWAP
NEW APPLICATION ENTERED
06/25/2021
Continuous trademark protection
Get notified about every new filing that threatens BIOHAVEN PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.